EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder

Masaki Kato, Masako Shiosakai, Kazuo Kuwahara, Katsuhiro Iba, Yuki Shimada, Mizuki Saito, Daisuke Sekine, Kazuo Aoki iD, Yuki Shiomi, Teruhiko Higuchi

CNS Drugs · 2024-12 · 38 (12) · 1003-1016

DOI: 10.1007/s40263-024-01124-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CNS Drugs, online erschienen am 18.10.2024. Verfasst von Masaki Kato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. Hauptthemen laut MEDLINE: Major Depressive Disorder, Thiophenes, Quinolones, Antidepressive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Otsuka Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Inadequate response to antidepressant monotherapy is common among patients with major depressive disorder (MDD). The efficacy and safety of adjunctive brexpiprazole 2 mg/day has recently been confirmed during the 6-week, randomized, placebo-controlled phase 2/3 (BLESS) study, which evaluated brexpiprazole at 1 mg/day and 2 mg/day versus placebo as adjunctive therapy to antidepressant therapies in 740 Japanese patients with MDD and an inadequate response to antidepressant monotherapy. This study evaluated the long-term safety and efficacy of adjunctive fixed-dose brexpiprazole 2 mg/day in Japanese patients with MDD. METHODS: An open-label, 52-week study enrolled rollover patients who completed the 6-week, double-blind, randomized, placebo-controlled phase 2/3 BLESS study (NCT03697603), and de novo patients aged ≥ 65 years. Patients were titrated to fixed-dose brexpiprazole 2 mg/day from Week 1. Safety assessments included treatment-emergent adverse events (TEAEs; primary outcome) and clinical and laboratory variables. Efficacy was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression-Improvement (CGI-I) scale, Hamilton Depression Rating Scale (HAM-D) 17-item total score, and Sheehan Disability Scale (SDS) score. RESULTS: In total, 247 patients [rollover, n = 216; de novo (previously unexposed), n = 31] were included in the safety/efficacy populations, and 138 (rollover, n = 132; de novo, n = 6; 55.9%) completed the study. Common TEAEs (incidence ≥ 10%) were weight gain [33.2% (n = 82)], akathisia [23.5% (n = 58)], nasopharyngitis [21.1% (n = 52)], and somnolence [10.5% (n = 26)]. TEAEs leading to treatment discontinuation occurred in 26.7% of patients receiving brexpiprazole and 58.1% of de novo patients. The mean (SD) increase in body weight from baseline to Week 52 [observed cases (OC)] was 4.2 (6.5) kg (n = 138); 44.5% (n = 110) had weight gain ≥ 7% at any postbaseline visit. There were no cases of tardive dyskinesia and no AEs related to suicide/suicide attempts. One death occurred (unknown cause), which was unrelated to study treatment. Improvements in the MADRS total score were observed from baseline over the course of the 52-week study [mean (SD) change at Week 52 (OC): - 7.3 (8.7)] for all patients receiving brexpiprazole. The overall MADRS response rate and remission rate in patients receiving brexpiprazole was 41.3% (n = 57) and 34.8% (n = 48), respectively, at Week 52 (OC). Improvements in CGI-S, HAM-D 17 item total score, and SDS mean scores were also observed from baseline over the 52-week study, with a mean (SD) change from baseline at Week 52 (OC) of - 0.8 (1.0), - 5.9 (6.3), and - 1.0 (2.2), respectively, indicating a sustained improvement in symptoms with long-term brexpiprazole treatment. CONCLUSIONS: This is the first study to evaluate the safety profile of brexpiprazole 2 mg/day in Japanese patients with MDD, including older adults, which is similar to previous reports, with no new safety risks, and continued efficacy over 52 weeks. STUDY REGISTRATION: ClinicalTrials.gov (NCT03737474; registered on 29 July 2018).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderThiophenesQuinolonesAntidepressive AgentsDrug Therapy, CombinationHumansFemaleMaleMiddle AgedDouble-Blind MethodAgedTreatment OutcomeJapanEast Asian People

Substanzen

brexpiprazoleThiophenesQuinolonesAntidepressive Agents

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
  • Clinical Development, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Clinical Development, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.
  • Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Shinagawa Grand Central Tower 2-16-4, Konan, Minato-ku, Tokyo, 108-8242, Japan.
  • Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Shinagawa Grand Central Tower 2-16-4, Konan, Minato-ku, Tokyo, 108-8242, Japan. aoki.kazuo@otsuka.jp.
  • Japan Depression Center, Tokyo, Japan.

ORCID-Profile: Kazuo Aoki

Förderung

  • Otsuka Pharmaceutical Co., Ltd.

Zitieren

APA

Kato, M., Shiosakai, M., Kuwahara, K., Iba, K., Shimada, Y., Saito, M., Sekine, D., Aoki, K., Shiomi, Y., & Higuchi, T. (2024). A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder. CNS Drugs, 38(12), 1003-1016. https://doi.org/10.1007/s40263-024-01124-w

Vancouver

Kato M, Shiosakai M, Kuwahara K, Iba K, Shimada Y, Saito M, et al. A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder. CNS Drugs. 2024;38(12):1003-1016. doi:10.1007/s40263-024-01124-w

BibTeX
@article{Kato2024,
  author = {Kato, Masaki and Shiosakai, Masako and Kuwahara, Kazuo and Iba, Katsuhiro and Shimada, Yuki and Saito, Mizuki and Sekine, Daisuke and Aoki, Kazuo and Shiomi, Yuki and Higuchi, Teruhiko},
  title = {A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder},
  journal = {CNS Drugs},
  year = {2024},
  volume = {38},
  number = {12},
  pages = {1003--1016},
  doi = {10.1007/s40263-024-01124-w}
}
Kostenlos starten →